Publications
& Policy

Our 2025 Annual Report provides a comprehensive overview of the association’s key achievements, outlines our priorities for the current year, and sets out our long-term strategic vision.

As Europe’s PE/VC ecosystem operates increasingly at scale and across borders, the EU‑Inc. proposal offers a practical and timely response for a more investment‑ready company framework. Now, the proposal’s core features must be preserved, renationalisation avoided,  and implementation accelerated, ensuring EU‑Inc. delivers real economic value across the full company lifecycle and incentives, strengthening Europe’s competitiveness while laying the groundwork for deeper Single Market integration.

Invest Europe responded to AMLA’s consultation on draft Regulatory Technical Standards under the AMLR, advocating for a proportionate, risk‑based application of Customer Due Diligence (CDD) to Private Equity, Venture Capital and Infrastructure Fund Management. The response supports AMLA’s objective of harmonisation while calling for clearer operational guidance to reflect closed‑ended fund structures, institutional investor bases and transaction‑driven business models. Invest Europe emphasised the need for simplified due diligence to function effectively in low‑risk contexts, for reliance on functionally equivalent evidence, and for safeguards against national gold‑plating that could undermine proportionality and supervisory convergence.

Detailed evidence and analysis of the European private equity and venture capital industry’s real contribution to employment, in 2024, and job creation, in 2023-24, and the far-reaching impact this has on the people, societies and economies of Europe.

Download the factsheets to see the European private equity and venture capital industry’s real contribution to employment, in 2024, and job creation, in 2023-24 in Norway and Sweden.

Europe stands at a crossroads for biotech and healthcare, as it continues to lose companies, capital, talent and clinical activity to more competitive ecosystems abroad. The European Biotech Act I’s delivery must be comprehensive and future-proof.  Invest Europe’s position sets out how the Act can become a true end‑to‑end ecosystem strategy. Without addressing remaining structural bottlenecks, Europe risks continued underperformance in a sector that is central to competitiveness, health security and strategic autonomy.

AI is at the centre of today’s conversations in private equity—but where does it truly add value?

In this response we highlight to European Insurance and Occupational Pensions Authority (EIOPA) our concerns that focusing draft supervisory statement specifically on private equity ownership models would create a de facto two-tiered regime which, in effect, would apply a higher, more onerous standard to a private equity acquirer.

In this response, EU policymakers should use the forthcoming revision of the banking framework, as suggested by the European Council, to introduce targeted and proportionate changes to the credit risk treatment of diversified long-term equity exposures under Article 133 of the Capital Requirements Regulation.

Weak IPO markets, fragmented capital markets, regulatory complexity and limited institutional capital continue to constrain exits across the investment lifecycle. While a private intermittent trading platform could play a complementary role in selected cases, Invest Europe's response stresses that any such solution must remain proportionate, issuer‑controlled and market‑led - and must not undermine the fund‑based model that underpins private investment in Europe.